文献速递乳腺癌放疗放疗物理与技术

局部放疗联合抗糖皮质激素诱导的肿瘤坏死因子受体(GITR)激动剂增强PD-L1阻断在小鼠乳腺癌模型中的抗肿瘤效应

Combination of local radiotherapy and anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) therapy augments PD-L1 blockade-mediated anti-tumor effects in murine breast cancer model.
PubMed 文献 · Radiother Oncol · 2023-11-02

本研究利用METABRIC乳腺癌数据集分析GITR表达与预后的关系,并在4T1小鼠三阴性乳腺癌模型中评估PD-L1阻断、局部放疗、抗GITR激动剂及其联合方案的效果。结果显示,在PD-L1阻断基础上同时联合局部放疗和抗GITR激动剂可显著抑制肿瘤生长和肺转移,并伴随肿瘤微环境和脾脏中CD8+ T细胞增加、调节性T细胞(Tregs)减少;而单独加用局部放疗或抗GITR激动剂未显著增强PD-L1阻断的疗效。

要点

  • METABRIC队列中TNFRSF18(编码GITR)高表达患者生存显著优于低表达者。
  • PD-L1阻断基础上单独加局部放疗或抗GITR激动剂未显著增强疗效。
  • 三联方案显著减少肿瘤生长和肺转移,伴CD8+ T细胞增加、Tregs减少。

核心结论

  • 局部放疗联合抗GITR激动剂显著增强了PD-L1阻断诱导的抗肿瘤免疫应答,为三者联合提供了临床前依据。

研究设计与样本

  • 研究分析METABRIC乳腺癌数据集以确定GITR在乳腺癌中的作用,并使用4T1小鼠三阴性乳腺癌模型(原发瘤和继发瘤)评估PD-L1阻断、局部放疗、抗GITR激动剂及其联合方案的疗效。
  • 通过肿瘤体积测量、体内生物发光成像和转移性肺结节计数评估肿瘤生长;采用流式细胞术和免疫组化检测肿瘤和脾脏中CD8+ T细胞和调节性T细胞(Tregs)的比例与表型;用酶联免疫吸附试验测定血浆细胞因子水平。

主要发现

  • 在METABRIC队列中,TNFRSF18(编码GITR)高表达患者的生存显著优于低表达患者。
  • 在PD-L1阻断基础上加用局部放疗或抗GITR激动剂,与单用PD-L1阻断相比未显著增强疗效。
  • 在PD-L1阻断基础上同时加用局部放疗和抗GITR激动剂,显著减少了肿瘤生长和肺转移。
  • 三联联合的获益伴随肿瘤微环境和脾脏中CD8+ T细胞增加、Tregs减少。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In this study, we investigated whether local radiotherapy (RT) and an anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) agonist could increase the efficacy of PD-L1 blockade. METHODS AND MATERIALS: We analyzed a breast cancer dataset from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) to determine the role of GITR in breast cancer. We used the 4T1 murine TNBC model (primary and secondary tumors) to investigate the efficacy of PD-L1 blockade, local RT, anti-GITR agonist, and their combinations. We assessed tumor growth by tumor volume measurements, in vivo bioluminescence imaging, and metastatic lung nodule counts to evaluate the effects of these treatments. Flow cytometry and immunohistochemistry determined the proportions and phenotypes of CD8+ T-cells and regulatory T-cells (Tregs) in the tumors and spleen. Plasma cytokine levels were measured by enzyme-linked immunosorbent assay. RESULTS: In the METABRIC cohort, patients with high expression of TNFRSF18, which encodes GITR, had significantly better survival than those with low expression. Adding local RT or anti-GITR agonist to PD-L1 blockade did not significantly augment efficacy compared to PD-L1 blockade alone; however, adding both to PD-L1 blockade significantly reduced tumor growth and lung metastasis. The benefits of the triple combination were accompanied by increased CD8+ T-cells and decreased Tregs in the tumor microenvironment and spleen. CONCLUSIONS: The combination of local RT and an anti-GITR agonist significantly enhanced the anti-tumor immune responses induced by PD-L1 blockade. These results provide the preclinical rationale for the combination of therapy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Song JY, Han MG, Kim Y, et al. Combination of local radiotherapy and anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) therapy augments PD-L1 blockade-mediated anti-tumor effects in murine breast cancer model. Radiother Oncol. 2023. PMID: 37925106. doi:10.1016/j.radonc.2023.109981

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。